Innate Immune Cells to the Help  by Lambrecht, Bart N. & Hammad, Hamida
Immunity
PreviewsInnate Immune Cells to the HelpBart N. Lambrecht1,2,3,* and Hamida Hammad1,2,*
1VIB Inflammation Research Center, University of Ghent, 9000 Gent, Belgium
2Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium
3Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands
*Correspondence: bart.lambrecht@ugent.be (B.N.L.), hamida.hammad@ugent.be (H.H.)
http://dx.doi.org/10.1016/j.immuni.2014.02.010
A study by Halim and Steer (2014) in this issue of Immunity shows that innate lymphoid cells type 2 (ILC2s)
are crucial for inducing adaptive T helper 2 immunity by providing interleukin-13. Another study by van Dyken
et al. (2014) shows that ILC2s control eosinophilia and alternative activation of macrophages.Chronic asthma is an inflammatory dis-
ease of the airway wall that leads to bron-
chial hyperreactivity and variable airway
obstruction. Eosinophils are the pre-
dominant myeloid cells infiltrating the
airway wall. Airway eosinophilia was long
believed to be controlled by allergen-
specific T helper 2 (Th2) lymphocytes pro-
ducing the interleukin-5 (IL-5) necessary
for eosinophil development, IL-4 driving
Th2 cell polarization and immunoglobulin
E (IgE) synthesis, and IL-13 driving goblet
cell metaplasia and bronchial hyperreac-
tivity. The precise signals that control the
development of Th2 lymphocytes upon
first encounter with allergens are not pre-
cisely understood. Upon inhalation of
allergens containing enzymes or TLR ago-
nists, airway dendritic cells and epithelial
cells communicate via innate pro-Th2
cytokines like granulocyte-macrophage
colony-stimulating factor (GM-CSF),
thymic stromal lymphopoietin (TSLP), IL-
25, and IL-33 (see Figure 1). Dendritic
cells (DCs) then migrate to the nodes
and induce Th2 cell polarization but do
not produce the prototypical cytokine
IL-4 that is necessary to drive Th2 cell
polarization. Therefore, induction of Th2
immunity has remained somewhat of an
enigma.
The dogma that eosinophilic inflamma-
tion in asthma is exclusively controlled by
adaptive immune cells has been recently
challenged because tissue eosinophilia
can also be controlled by innate lympho-
cytes that lack antigen specificity (Neill
et al., 2010). Innate lymphoid cells type 2
(ILC2; also known as natural helper cells
or nuocytes) accumulate in the lungs
shortly after allergen exposure (Barlow
et al., 2012; Halim et al., 2012). These
ILC2s share many features with Th2 cells:
they produce IL-5 and IL-13 and expressthe GATA3 transcription factor and che-
mokine receptors CCR4, CCR8, and
CRTH2. The precise contribution of
ILC2s to asthma pathogenesis is currently
unclear. Most studies describing a
role for ILC2s have been performed
by comparing RAG1-deficient mice
that lack T cells and B cells, with
Rag2/Il2rg/ mice that lack T and B
cells and all ILCs. This might have overes-
timated the contribution of ILC2s in
asthma. Also it is unclear whether ILC2s
would influence generation of adaptive
Th2 immunity or the function of DCs in
mice with a fully functional immune
system and could help explain the allerge-
nicity of certain antigens.
In this issue of Immunity, Halim and
Steer have studied C57Bl/6 mice re-
constituted with RORa-deficient bone
marrow from ‘‘staggerer’’ mice (Rorasg/sg
mice) (Halim and Steer, 2014). These
mice lack ILC2s, yet they have a fully func-
tional immune system and can develop
normal Th2 cell responses in vitro (Halim
et al., 2012). After inhalation of papain,
ILC2s were rapidly recruited to the lungs
of wild-type (WT) mice. When challenged
a few weeks later with a second series
of papain exposures, mice mounted an
even more robust eosinophilia, accompa-
nied by heightened IgE responses, result-
ing from a GATA3+ CD4+ Th2 adaptive
immune response to papain. Whereas
the early eosinophilia was intact, the
heightened challenge response was abol-
ished in Rag1/ mice lacking T and B
cells. In Rorasg/sg mice, both the early
innate and late heightened eosinophilic
and IgE responses were abolished. As
only ILC2s are lacking in these mice, this
pointed to an enforcing role for ILC2s in
adaptive Th2 immunity. The most striking
observation of the paper is that ILC2s pro-Immunity 4mote Th2 immunity not through IL-4
(which they hardly produce) but by provi-
sion of IL-13. IL-4 and IL-13 can use the
same IL-4Ra chain to signal to T cells,
and several models have illustrated that
Th2 immunity can occur independently
of IL-4. Papain is the first model to depend
exclusively on IL-13 from ILC2s. In sup-
port, Halim and Steer show that Th2
immunity to papain and coadministered
OVA in Rorasg/sg mice is restored by WT
ILC2s, but not by IL-13-deficient ILC2s.
What remains to be shown is whether
IL-13 directly affects naive T cells or indi-
rectly affects other cells like DCs. The
authors do show that IL-13 stimulates
migration of activated DCs to the lung
draining nodes. An experiment in which
T cells or DCs selectively lack the IL-4Ra
chain could answer this question.
In a second article, van Dyken et al.
have studied how ILCs contribute to aller-
genicity of chitin (van Dyken et al., 2014).
Chitin is a polysaccharide found in the
exoskeleton of parasites and arthropods
and the hyphal cell wall of fungi.
When inhaled, it immediately causes
eosinophil-rich airway infammation and
accumulation of alternatively activated
macrophages (AAMs) that typically pro-
duce arginase and express chitinases
under the influence of IL-4 and/or IL-13.
The authors injected 50-70 mm chitin
particles into the trachea, which led to
an innate lung immune response within
the first 24 hr that was dependent on
IL-5 and IL-13. As shown with Il5RFP
reporter mice and Il13smart mice (that
report on IL-13 protein expression without
affecting endogenous IL-13 levels), the
source of these cytokines was shown to
be ILC2s exclusively. Whereas the eosin-
ophilia was dependent on ILC2-derived
IL-5 and IL-13, the AAM phenotype was0, March 20, 2014 ª2014 Elsevier Inc. 313
Figure 1. Early Recognition of Inhaled Allergens by Innate Immune Cells and Epithelial Cells
When allergens like the enzyme papain or the polysaccharide chitin are inhaled, they are recognized by
epithelial cells and dendritic cells. Epithelial cells produce pro-Th2 cell cytokines like IL-25, TSLP, and
IL-33 that activate ILC2s. The ILC2s then produce IL-13, which can activate DCs, so that these start
inducing adaptive CD4 Th2 cell immunity (and IgE production) after migration to the draining nodes.
ILC2s also produce IL-5 and IL-13, which drive eosinophila and alternative activation of arginase-
producing macrophages. The ILCs also suppress the development of neutrophilic airway inflammation
by unclear mechansims, involving suppression of gd T cell-derived IL-17.
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IL-13. By using dual photon microscopy
to image deep in the lung tissue, the au-
thors found ILC2s in close vicinity to blood
vessels, explaining how IL-5 could also be
released in the bloodstream to affect
bone-marrow output of eosinophils. To
delete ILC2s in mice with a functional
immune system, the authors cleverly
made use of Cre-expressing mice in
which ILCs get killed as soon as they
commit to IL-5 or IL-13 cytokine produc-
tion. ILC deletion led to reductions in early
eosinophilia and AAM induction, compa-
rable to levels seen in Rag2/Il2rg/
mice. Unexpectedly, ILC2 deletion also
led to increased production of tumor
necrosis factor alpha (TNF-a), IL-1b, and
IL-23 and increased production of IL-17
by innate gd T cells, causing increased
airway neutrophilia. These suppressive
effects of ILC2s on neutrophil and gd314 Immunity 40, March 20, 2014 ª2014 ElseT cell activation were not due to defective
IL5 and/or IL-13 production but to an
unidentified mechanism of suppression.
Barrier epithelial cells are ever more
implicated in asthma pathogenesis,
because they are able to sense exposure
to allergens via pattern recognition recep-
tors (PRRs) and activate DCs and other
innate immune cells, through the secre-
tion of TSLP, GM-CSF, IL-1, IL-33, and
IL-25 (Lambrecht and Hammad, 2012).
ILC2s express receptors for TSLP, IL-33,
and IL-25. Chitin inhalation induced these
pro-Th2 cytokines in the lung, but the
combined absence of all three cytokine
receptors did not affect ILC2 number,
merely their activation status and produc-
tion of IL5 and IL-13.
In conclusion, these papers help
unravel some of the mysteries surround-
ing induction of acute type 2 immunity to
inhaled model allergens. However, theyvier Inc.do not yet answer the important question
of whether ILC2s can be solely respon-
sible for causing full-blown and persistent
asthmatic airway inflammation to com-
mon environmental allergens, often
accompanied by goblet cell metaplasia,
airway wall remodeling, and bronchial
hyperreactivity, so typical of chronic
asthma. ILC2-driven asthma in the
absence of Th2 cell immunity could be
responsible for causing asthma in nonal-
lergic asthmatics. Many of these patients
also have chronic rhinosinusitis and nasal
polyposis, known to contain many
CRTH2+ GATA3+ ILC2s (Mjo¨sberg et al.,
2011). Overproduction of epithelial cyto-
kines TSLP, IL-33, or IL-25 might intrinsi-
cally activate the ILC2 system, thus
causing salient features of asthma and
polyposis without the accompanying IgE
induction so typical of adaptive Th2 cell
immunity. Another point that needs to be
addressed is how ILCs communicate
with DCs and epithelial cells to promote
Th2 cell immunity. Some of the functions
of ILC2s (like suppression of Th17 and
gd T cell responses) do not depend on
IL-5 and IL-13, and it will important to fully
understand how this might work. The
technical and conceptual advance
offered by the two papers paves the way
for these more mechanistic studies.
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